Immuneering (US:IMRX) Globenewswire·2025-03-20 20:05Core Insights - Immuneering Corporation reported positive data from its ongoing Phase 2a trial of IMM-1-104, showing an overall response rate (ORR) of 43% and a disease control rate (DCR) of 86% in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer [3][4] - The company has entered a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo for non-small cell lung cancer [4][8] - Cash runway has been extended into 2026, providing sufficient funding for ongoing operations [9] Clinical Developments - The Phase 2a trial of IMM-1-104 demonstrated promising results, with an ORR of 50% when combined with modified FOLFIRINOX, compared to historical benchmarks of 23% and 32% for the respective chemotherapy agents [3][4] - Plans are underway for a potential global pivotal trial of IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel [3][4] - Additional combination arms for IMM-1-104 are expected to be initiated in 2025, including studies with a BRAF inhibitor, a G12C inhibitor, and a PD-1 inhibitor [4][8] Financial Performance - As of December 31, 2024, the company reported cash and cash equivalents of $36.1 million, a decrease from $85.7 million as of December 31, 2023 [7][19] - Research and development (R&D) expenses for Q4 2024 were $14.9 million, up from $11.9 million in Q4 2023, reflecting increased clinical costs related to IMM-1-104 [7][17] - The net loss for Q4 2024 was $18.1 million, or $0.58 per share, compared to a net loss of $15.1 million, or $0.52 per share, for Q4 2023 [7][17] Leadership Changes - Dr. Igor Matushansky has been appointed as Chief Medical Officer to oversee clinical activities and development programs [4][5]